Specific mutations in respiratory syncytial virus (RSV) fusion protein can cause palivizumab resistance. We assessed the incidence of sequence polymorphisms and palivizumab resistance in clinical RSV isolates collected from immunoprophylaxisnaive subjects. Polymorphisms were identified at low frequency, and only polymorphic mutations in antigenic site A (,1% of all polymorphisms) conferred palivizumab resistance.
Specific mutations in respiratory syncytial virus (RSV) fusion protein can cause palivizumab resistance. We assessed the incidence of sequence polymorphisms and palivizumab resistance in clinical RSV isolates collected from immunoprophylaxisnaive subjects. Polymorphisms were identified at low frequency, and only polymorphic mutations in antigenic site A (,1% of all polymorphisms) conferred palivizumab resistance.
Respiratory syncytial virus (RSV) is an important pathogen that causes annual worldwide epidemics of bronchiolitis and pneumonia in infants and young children [1, 2] . The hospitalization rate for RSV disease in infants with a history of premature birth or congenital heart disease is higher than the general infant population [3, 4] . Palivizumab, an RSV-specific humanized monoclonal antibody (mAb), has been approved for use in the United States since 1998 [5] . Palivizumab binds antigenic site A, a highly conserved region on the RSV fusion (F) protein, by convention located between amino acids 258 and 275. Single amino acid substitutions (N262S, N268I, K272N/M/T/Q, and S275F/L) in site A that render RSV largely resistant to neutralization by palivizumab in cell culture or in cotton rat models have been identified elsewhere [6] [7] [8] [9] . Some of these site A mutations (K272E, K272Q, S275F/L) were also reported in a small number of RSV variants isolated from patients who had received palivizumab [9, 10] . Recently, Adams et al [11] have proposed that a mutation from asparagine (N) to serine (S) adjacent to site A at position 276 in RSV A could also confer partial resistance to palivizumab. Serine is the consensus amino acid in RSV B at position 276.
The natural polymorphic amino acid changes of F protein and their potential association with resistance to palivizumab have not been investigated extensively, nor is it known whether any polymorphic changes outside site A could affect neutralization by palivizumab. The work presented here has 3 aims: (1) to define the natural polymorphism of F protein detected in clinical isolates collected from treatment-naive subjects during 2003-2008; (2) to determine the incidence of mutations in antigenic site A in RSV isolated from these naive subjects; and (3) to evaluate the palivizumab susceptibility in clinical isolates or recombinant RSV (rRSV) with identified polymorphic changes, especially those near or within site A.
MATERIALS AND METHODS
Samples of nasopharyngeal secretions were collected at the time of hospitalization for respiratory illness (from 2003 to 2008) from subjects (majority aged #2 years) not undergoing immunoprophylaxis with either palivizumab or motavizumab (an affinity-enhanced mAb derived from palivizumab). The majority of clinical RSV isolates (186 samples) were collected from subjects across the United States (California, Colorado, Connecticut, Illinois, North Carolina, New Mexico, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia) with the remainder of the isolates from Australia (n 5 19), Beer Sheva, Israel (n 5 12), Utrecht, Netherlands (n 5 12), Italy (n 5 9), Gebze, Turkey (n 5 8), Santiago, Chile (n 5 6), and Canada (n 5 2). Samples that tested positive for RSV by reversetranscription polymerase chain reaction or other diagnostic tests were used for genotypic analysis of the F protein as described [9] . Phylogenetic analysis of a total of 254 F protein sequences of RSV was conducted, and polymorphisms (as defined in Results) in the F protein were identified by comparison to reference sequences RSV A2 and RSV B 9320 (GenBank IDs M74568 and AY353550, respectively). The phenotypic susceptibility of RSV isolates or rRSV-containing F protein sequence variations was determined by a palivizumab microneutralization assay, as described elsewhere [9] . The condition used for rRSV complementary DNA construction containing desired mutations and for rescuing rRSV are described elsewhere [12] . The rRSV recovered in the supernatant was biologically cloned 2-3 times in sequential limiting dilutions in 96-well plates containing HEp-2 cells. The viral clones were amplified 2-3 times in HEp-2 cells before characterization. Viral replication of palivizumab-resistant rRSV variants was further determined in mice. Briefly, 6-week-old BALB/c mice were lightly anesthetized with isoflurane and intranasally inoculated with 50 lL of phosphate-buffered saline containing 1 3 10 6 focus-forming units of rRSV A2 wide-type or mutant variants. Mice were sacrificed and were harvested at 2, 3, 4, 5, and 6 days after infection. Viral titers in lung homogenates were determined by measuring the viral protein expression in Vero cells after infection for 5 days in vitro. Results are expressed as focus-forming units per gram of lung tissue.
RESULTS
Phylogenetic analysis was performed on 145 RSV A and 109 RSV B F protein sequences obtained from nasal specimens collected from subjects who did not receive immunoprophylaxis from 2003 to 2008, spanning 8 countries (Australia, Canada, Chile, Israel, Italy, the Netherlands, Turkey, and the United States). We defined polymorphisms as variations from the amino acid that appears most frequently at that position in reference sequences from GenBank, which were also found in RSV isolates recovered from immunoprophylaxis-naive subjects. We also considered a variation polymorphic when the variation in one RSV subtype (A or B) was the consensus amino acid in the other subtype at that same position. Because palivizumab binds to the extracellular domain of the mature F protein, we only analyzed the polymorphic sequence variations found in this region (amino acids 25-109 and 137-524). There were 46 polymorphic sequence variations observed in 39 positions in RSV A and 34 polymorphic amino acid changes in 32 positions in RSV B (Tables 1 and 2 ). Amino acid variations were observed with frequencies ,1% in most cases for both RSV A and RSV B.
Variations occurred more frequently at positions 45, 66, 100-105, 278, 326, 470, and 518. We found 2 RSV A isolates encoding polymorphisms (N262D and S275F) within antigenic site A, each at a frequency of 0.7% (1/145). Bordering antigenic site A, 2 of 145 (1.4%) RSV A isolates contained mutation N276S, and 2 of 109 (1.8%) RSV B variants contained S276N. To determine whether these natural polymorphic variations, especially those near or within antigenic site A, affected RSV susceptibility to neutralization by palivizumab, .50 clinical isolates encoding the most common amino acid polymorphisms recovered from nasal specimens were tested in microneutralization assays. In addition, rRSVs were generated to express F protein polymorphisms bracketing antigenic site A (positions 238-295) when clinical isolates encoding these variations were not recovered in culture. The results (Tables 1 and 2) indicate that isolates or rRSVs containing F protein polymorphisms outside antigenic site A were as sensitive to neutralization by palivizumab as wild-type RSV, all characterized by median inhibitory concentration values within a 5-fold range. In contrast, recombinant viruses encoding N262D and S275F variations in antigenic site A were resistant to neutralization at the highest palivizumab concentration tested (.100 lg/mL), consistent with previous results obtained with mAb-resistant mutants selected in cell culture [9] . Notably, variations N276S in RSV A and S276N in RSV B did not confer resistance to palivizumab.
CONCLUSIONS
Compared with other virus surface proteins, the amino acid sequence of the RSV F protein appears relatively stable. In samples collected from prophylaxis-naive subjects between 2003 and 2008, the frequency of amino acid changes at most positions was ,1% in the extracellular portion of the F protein. Furthermore, our phenotypic analysis demonstrates that the polymorphic changes bordering antigenic site A (amino acids 258-275) did not prevent palivizumab-mediated neutralization. Similar results were also obtained for RSV isolated from subjects in whom palivizumab immunoprophylaxis failed containing nonpolymorphic changes outside antigenic site A (unpublished data). To date, all confirmed palivizumab-resistant mutations occur within antigenic site A. It was suggested recently that an N276S variant identified in an RSV A isolate recovered from an infant dosed with palivizumab could confer partial resistance to palivizumab and promote selection of a secondary mutation at 272 from K to E, leading to complete resistance [11] . The K272E variant was detected after 2 passages in vitro in the presence of palivizumab, as seen elsewhere for in vitro-generated mAb-resistant mutants [9] . To date, single amino acid changes at position 276 have been detected neither in RSV passaged in the presence of palivizumab in vitro nor observed in RSV collected from subjects in whom palivizumab immunoprophylaxis failed. In this study, N276S variants were observed in RSV A during the 2007-2008 RSV season in Israel and Turkey, and S276N variants were observed in RSV B isolates circulating in 2004 and 2005 in the United States. Furthermore, the N276S change has become predominant in RSV circulating in 3 Canadian communities from 2008 to 2010 [13] . Therefore it was important to characterize these RSV A and RSV B polymorphs for their susceptibility to palivizumab to determine whether naturally resistant RSV was increasing in the community. To this end, we have extensively evaluated the palivizumab susceptibility of both recovered isolates and rRSV expressing N276S or S276N in RSV A or RSV B polymorphs. The microneutralization data indicated that these polymorphic changes did not alter the neutralization of RSV by palivizumab (Tables 1 and 2 ).
Our conclusion that the N276S variant in RSV A did not confer any resistance to palivizumab is contrary to that of Adams et al [11] . In our previous studies, isolates containing resistance changes in antigenic site A (including K272E) often were detected as mixtures with wild-type RSV. Furthermore, neutralization assays can be affected by a minor subpopulation of a resistant mutant (10%) in a background of wild-type virus below the limit of detection (20%) of standard-sequence electrophoretograms (data not shown). In the study reported by Adams et al [11] , it is possible that there was a minor population (,10%) of K272E N276S variant in the nasal specimen along with the N276S variant polymorph, which contributed to the apparent resistance to palivizumab. We report here for the first time the presence of amino acid changes (N262D and S275F) in antigenic site A in RSV isolated from naive subjects; these mutations are associated with resistance to palivizumab. They were observed in 2 of 145 RSV A sequences as a subpopulation mixed with wild-type virus. The rate of this natural resistance polymorphism is significantly lower than the rate of palivizumab-resistant mutation (0.7% vs 5%) identified in RSV collected from human subjects in whom palivizumab immunoprophylaxis failed [9] . The natural occurrence of these resistant variants in persons not previously exposed to palivizumab may be due to random mutation. It is also possible that these variants might arise under selective pressure from maternal or host neutralizing antibodies directed against antigenic site A. In general, the emergence and outgrowth of virus with resistance mutations in the absence of drug selection should only occur if the fitness costs are low. When replicative fitness was examined in vitro using rRSV mutants, most drug resistance mutations (S275F, S275L, K272E, K272Q) were associated with impaired replication and growth kinetics in the absence of selection compared with parental rRSV A2 [9] . Furthermore, when tested in a mouse model, their growth was not enhanced in vivo, and most replicated poorly compared with parental wild-type rRSV A2 strain (Figure 1) . The level of replication of all mutant variants was significantly lower than that of wild-type variant at peak replication on day 5. These results suggest that variants containing palivizumab-resistant mutations may have a growth disadvantage in the absence of palivizumab-selective pressure.
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Financial support. This work was supported by MedImmune. Figure 1 . Growth kinetics of wild-type (wt) recombinant respiratory syncytial virus (rRSV) A2 and palivizumab-resistant mutant variants in mice. BALB/c mice were intranasally inoculated with 1 3 10 6 focusforming units of rRSV A2 wt or mutant variants rRSV A2_S275F, S275L, K272Q, and K272E. Virus titers in lung homogenotes of animals killed at the indicated times after infection were determined on Vero cells. Growth capacity was expressed as plaque focus-forming units (FFU) per gram of lung tissue, and values represent means 6 standard deviations for 7 animals. *P , .05 (t test).
